A team of researchers from the Translational Oncology Research Centre (TORC) of Vrije Universiteit Brussel (VUB), in ...

A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The findings showcase a ...

Delayed diagnosis causes a significant disadvantage for Hungarian patients adding cost and complexity to the already stretched healthcare system.

The team tackled a critical challenge in treating multiple myeloma-a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.

AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for ...

Treatment with fixed-dose subcutaneous Sarclisa plus Pomalyst and dexamethasone ... We look forward to sharing full results ...

A groundbreaking study recently published in the New England Journal of Medicine has shown that a combination of two existing ...

Seattle-based Umoja Biopharma has raised a $100 million Series C round. With the funding, announced Tuesday, Umoja wants to ...

John D. Carpten, Ph.D., a prominent genomics researcher and chief scientific officer at cancer research and treatment institution City of Hope, has these concerns.

During a Case-Based Roundtable® event, Rahul Banerjee, MD, discussed approaches to dosing and tolerability when using ...

Kate Middleton left a lasting impression on one of the cancer patients at the hospital where she was treated for her health ...